#ASH26 First-in-human clinical trial of an off-the-shelf allogeneic megakaryocyte product for refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation https://t.co/ERH1f2qGdr
CMV reactivation is common after CAR T-cell therapy for #LBCL, including in the 2L setting. Corticosteroid exposure is a major risk factor for CMV reactivation. Read in Blood ICT: https://t.co/BiyuVsOzWz
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. https://t.co/sWshCKSBQw
Nature Genetics: After CAR19 for lymphoma, clonal hematopoiesis expanded and was linked to cytopenia, poor immune recovery and tMN.
https://t.co/5AkHAiJdb0